

## Supplementary Figure 1. AXL enrichment in latent and metachronous brain-tropic cells.

A, Immunoblots showing EGFR and HER2 expression in HCC1954 PA, Lat, S-BM and M-BM cells. B, Relative quantification of oncospheres formed by SKBR3 PA, Lat and M-BM cells seven days post-treatment with Tucatinib (3µM) and Lapatinib (1µM) compared to DMSO control. Data are presented as mean  $\pm$  SEM. One-way ANOVA was used, followed by the Dunnett test. \*\*, P < 0.01. \*\*\*\*, P < 0.0001. ns: not significant. C-D, Volcano plots showing differentially expressed genes in HCC1954 Lat and M-BM cells. Normalized gene count TPM. E, AXL mRNA levels in HCC 1954 Lat, S-BM and M-BM cells normalized to PA. Unpaired Student t test. \*\*\*\*, P < 0.001. ns: not significant. F, Immunoblot showing AXL expression in HCC1954 PA, Lat and S-BM derivative and M-BM derivative cells. G, AXL mRNA levels in SKBR3 Lat and M-BM cells normalized to PA. Unpaired Student t test. \*\*\*\*, P < 0.001. H, Immunoblot showing AXL expression in SKBR3 PA, Lat and M-BM cells. I, Immunoblots show no interaction between immunoprecipitated AXL and EGFR or HER2 in HCC1954 Lat and M-BM cells. J, Representative image of AXL IHC on brain metastatic lesion in mice bearing SKBR3 M-BM cells. K, Total AXL expression (mean fluorescence intensity of surface expression and surface plus intracellular expression (whole)) in HCC1954 Lat and M-BM cells. L, Immunoblot analysis of subcellular fractions from SKBR3 Lat and M-BM cells showing AXL localization and purity of subcellular fractions. GAPDH (CE, cytoplasmic extract), TFRC (ME, membrane extract), Lamin-B1 (NE, soluble nuclear extract) and Histone-3 (CB, chromatic bound extract).